Document is current

Article History

Received: 3 November 2017

Accepted: 3 January 2018

First Online: 25 January 2018

Ethics approval and consent to participate

: Not applicable

: Not applicable

: JZ has no financial or non-financial competing interests. AJA reports research funding from Dendreon, Sanofi, Bayer, Pfizer, Novartis, Janssen, Medivation, Astellas Pharma, Gilead Sciences, Genentech, and Active Biotech; consultant/advisory roles from Bayer, Sanofi, Novartis, Dendreon, Medivation, Janssen, and Pfizer; and speakers’ bureau for Dendreon and Sanofi. TWF reports research funding from Janssen, ImClone Systems, Aragon Pharmaceuticals, and GlaxoSmithKline; consultant/advisory role for Pfizer, Genentech, AstraZeneca, and Clovis Oncology; and speakers’ bureau for Sanofi, Dendreon, and Astellas/Medivation. WK reports consultant/advisory roles for Dendreon, Bayer, and Genentech. SKP reports research funding from Medivation; consulting/advisory roles for Pfizer, Novartis, Aveo, Myriad Pharmaceuticals, Genentech, Exelixis, Bristol-Myers Squibb, Astellas Pharma, Ipsen, and Eisai. DJG reports research funding from Exelixis, Genentech, Janssen, Novartis, Pfizer, Viamet Pharmaceuticals, Astellas Pharma, Bristol-Myers Squibb, Millennium, Acerta Pharma, Bayer, GlaxoSmithKline, Dendreon, AstraZeneca, and Sanofi; consultant/advisory roles from Bayer, Dendreon, Exelixis, Medivation, Novartis, Pfizer, Sanofi, GSK, Astellas Pharma, Innocrin Pharma, Bristol Myers Squibb, Genentech, Janssen, Acceleron Pharma, Celgene, Merck Sharp & Dohme, and Myovant Sciences; and speakers’ bureau for Dendreon, Novartis, Sanofi, and Bayer. TZ reports research funding from Janssen, Pfizer, Acerta Pharma, Novartis, Regeneron, and Stemcentrx; consultant/advisory roles for Janssen, Bayer, Genentech, Sanofi, and Exelixis; and ownership/employment (spouse) in Capio BioSciences.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.